In addition, hiding conflicts of interest deprives the public (and other researchers) to properly evaluate the validity of one's work. Certainly, one has a different view of the validity of the arguments in Fiore's piece once one becomes aware of his long history of financial relationships with Big Pharma. It is unfair to readers to deprive them of this relevant information. Plus, it is unfair to the journal, because the image of the journal itself could become tarnished if it becomes known that an author hid relevant financial conflicts from readers.

Because of the importance of this issue, I have written to the editorial staff of JAMA, urging them to publish a corrective statement, requiring Dr. Fiore to disclose his long and intensive history of conflicts of interest with pharmaceutical companies that manufacture smoking cessation drugs.

This provision is going to wreak havoc with the industry. The agency is determined that it cannot extend the grandfather date beyond 2007. This means that any product not on the market as of 2007 (which includes almost all electronic cigarette products) must either obtain a new product approval or a substantial equivalence determination. Given the snail's pace at which the FDA has processed cigarette substantial equivalence determinations, this could result in a literal quagmire of pending applications for the more than 250 brands of e-cigarettes currently on the market.

LAST：Wholesale High Quality IGO W3 RDA Atomizr IGO W3 |NEXT：Top leading green smoke x6 vaporizer from kamry, kamry wholesale x6 ecg kit